Our results showed that SC patients had a significantly higher serum ALT level at baseline than did non-SC patients (Table 1), which was partially consistent with Tseng’s report that a higher serum ALT level correlated with earlier SC in lamivudine-treated chronic hepatitis B patients [27]. This evidence concerns the gene GPT and chronic hepatitis B virus infection.